COMPARISON OF ANALYSIS APPROACHES FOR PHASE III CLINICAL TRIALS IN AMYOTROPHIC LATERAL SCLEROSIS

被引:20
|
作者
Healy, Brian C. [1 ,2 ]
Schoenfeld, David [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
amyotrophic lateral sclerosis; clinical trial; longitudinal analysis; sample size calculations; survival analysis; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL RATING-SCALE; LONGITUDINAL DATA; ALS; MODELS; MULTICENTER;
D O I
10.1002/mus.23392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores. Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated. Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality. Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches. Muscle Nerve 46: 506-511, 2012
引用
收藏
页码:506 / 511
页数:6
相关论文
共 50 条
  • [41] Clinical trials in amyotrophic lateral sclerosis: The tenuous past and the promising future
    Choudry, RB
    Cudkowicz, ME
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12) : 1334 - 1344
  • [42] Homozygosity analysis in amyotrophic lateral sclerosis
    Mok, Kin
    Laaksovirta, Hannu
    Tienari, Pentti J.
    Peuralinna, Terhi
    Myllykangas, Liisa
    Chio, Adriano
    Traynor, Bryan J.
    Nalls, Michael A.
    Gurunlian, Nicole
    Shatunov, Aleksey
    Restagno, Gabriella
    Mora, Gabriele
    Leigh, P. Nigel
    Shaw, Chris E.
    Morrison, Karen E.
    Shaw, Pamela J.
    Al-Chalabi, Ammar
    Hardy, John
    Orrell, Richard W.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2013, 21 (12) : 1429 - 1435
  • [43] Clinical neurorestorative progress in amyotrophic lateral sclerosis
    Chen, Lin
    Huang, Hongyun
    Xi, Haitao
    Mao, Gengsheng
    JOURNAL OF NEURORESTORATOLOGY, 2015, 3 : 109 - 114
  • [44] A clinical trial of verapamil in amyotrophic lateral sclerosis
    Miller, RG
    Smith, SA
    Murphy, JR
    Brinkmann, JR
    Graves, J
    Mendoza, M
    Sands, ML
    Ringel, SP
    MUSCLE & NERVE, 1996, 19 (04) : 511 - 515
  • [45] Amyotrophic lateral sclerosis: update on clinical management
    Norris, Simone P.
    Likanje, Marie-France N.
    Andrews, Jinsy A.
    CURRENT OPINION IN NEUROLOGY, 2020, 33 (05) : 641 - 648
  • [46] A clinical trial of dextromethorphan in amyotrophic lateral sclerosis
    Gredal, O
    Werdelin, L
    Bak, S
    Christensen, PB
    Boysen, G
    Kristensen, MO
    Jespersen, JH
    Regeur, L
    Hinge, HH
    Jensen, TS
    ACTA NEUROLOGICA SCANDINAVICA, 1997, 96 (01): : 8 - 13
  • [47] Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole
    Corcia, Philippe
    Gordon, Paul H.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 359 - 366
  • [48] Geographical distribution of clinical trials in amyotrophic lateral sclerosis: a scoping review
    Garcia-Parra, Beliu
    Guiu, Josep M.
    Povedano, Monica
    Marino, Eduardo L.
    Modamio, Pilar
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2024, 25 (3-4) : 376 - 381
  • [49] Phrenic nerve study as outcome in clinical trials for amyotrophic lateral sclerosis
    Pinto, Susana
    De Carvalho, Mamede
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2021, 22 : 9 - 13
  • [50] A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
    Shefner, Jeremy M.
    Cudkowicz, Merit E.
    Hardiman, Orla
    Cockroft, Bettina M.
    Lee, Jacqueline H.
    Malik, Fady, I
    Meng, Lisa
    Rudnicki, Stacy A.
    Wolff, Andrew A.
    Andrews, Jinsy A.
    Van Damme, Philip
    Korngut, Lawrence
    Johnston, Wendy
    O'Connell, Colleen
    Grant, Ian
    Turnbull, John
    Shoesmith, Christen
    Zinman, Lorne
    Botez, Stephan
    Genge, Angela
    Dionne, Annie
    Couratier, Philippe
    Attarian, Shahram
    Pouget, Jean
    Camu, William
    Desnuelle, Claude
    Salachas, Francois
    Corcia, Philippe
    Meyer, Thomas
    Petri, Susanne
    Ludolph, Albert
    Calvo, Andrea
    Lunetta, Christian
    Silani, Vincenzo
    van den Berg, Leonard
    de Carvalho, Mamede
    Mora Pardina, Jesus
    Young, Carolyn
    Al-Chalabi, Ammar
    Radunovic, Aleksander
    Hanemann, Clemens
    Ladha, Shafeeq
    Goyal, Namita
    Ravits, John
    Lewis, Richard
    Joyce, Nanette
    Oskarsson, Bjorn
    Katz, Jonathan S.
    So, Yuen
    Quan, Dianna
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2019, 20 (7-8) : 584 - 594